MDDI Online is part of the Informa Markets Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

BioVentrix Scores ‘High Priority’ Reimbursement in Germany

The San Ramon, CA-based company has developed the Revivent TC TransCatheter Ventricular Enhancement System, a technology for left ventricular remodeling after a heart attack.

Image Courtesy of BioVentrix

BioVentrix has received the renewal of the highest priority reimbursement in Germany for its transcatheter device for left ventricular remodeling after a heart attack.

The San Ramon, CA-based company said it has achieved NUB Status 1 designation from InEk, the German Institute for Hospital Remuneration for the Revivent TC TransCatheter Ventricular Enhancement System.

The NUB process enables participating German hospitals to receive full reimbursement plus a supplemental payment when utilizing groundbreaking medical technologies not listed in the existing German healthcare system. NUB Status 1 was only assigned to a handful of innovative technologies. This is the fourth consecutive year that the Revivent TC System has achieved this status in 100+ hospitals in Germany.

The Revivent TC System is used in the Less Invasive Ventricular Enhancement (LIVE) procedure, to exclude scar tissue on the left ventricle that has resulted from a heart attack, so the healthy portion of the heart can function more efficiently. Micro-anchors are implanted and designed to remodel the heart to a more normal shape and size and reduce wall stress, which has the potential to improve blood flow throughout the body.

BioVentrix won CE mark for Revivent in 2016. The company received Breakthrough Device Designation from FDA for the Revivent TC Transcatheter Ventricular Enhancement System in November of 2019.

500 characters remaining